Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 181

1.

Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes.

Heise T, Nosek L, Bøttcher SG, Hastrup H, Haahr H.

Diabetes Obes Metab. 2012 Oct;14(10):944-50. doi: 10.1111/j.1463-1326.2012.01638.x. Epub 2012 Jul 10.

PMID:
22726241
[PubMed - indexed for MEDLINE]
2.

A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec.

Korsatko S, Deller S, Koehler G, Mader JK, Neubauer K, Adrian CL, Thomsen H, Haahr H, Pieber TR.

Clin Drug Investig. 2013 Jul;33(7):515-21. doi: 10.1007/s40261-013-0096-7.

PMID:
23749405
[PubMed - indexed for MEDLINE]
3.

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady-state conditions in type 1 diabetes.

Heise T, Hermanski L, Nosek L, Feldman A, Rasmussen S, Haahr H.

Diabetes Obes Metab. 2012 Sep;14(9):859-64. doi: 10.1111/j.1463-1326.2012.01627.x. Epub 2012 Jun 7.

PMID:
22594461
[PubMed - indexed for MEDLINE]
4.

Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus.

Korsatko S, Deller S, Mader JK, Glettler K, Koehler G, Treiber G, Urschitz M, Wolf M, Hastrup H, Søndergaard F, Haahr H, Pieber TR.

Drugs Aging. 2014 Jan;31(1):47-53. doi: 10.1007/s40266-013-0138-0.

PMID:
24263619
[PubMed - in process]
Free PMC Article
5.
6.

Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes.

Parkner T, Laursen T, Vestergaard ET, Hartvig H, Smedegaard JS, Lauritzen T, Christiansen JS.

Diabet Med. 2008 May;25(5):585-91. doi: 10.1111/j.1464-5491.2008.02418.x.

PMID:
18445172
[PubMed - indexed for MEDLINE]
7.
8.

Glucose-Lowering Effect of Insulin Degludec is Independent of Subcutaneous Injection Region.

Nosek L, Coester HV, Roepstorff C, Thomsen HF, Kristensen NR, Haahr H, Heise T.

Clin Drug Investig. 2014 Sep;34(9):673-9. doi: 10.1007/s40261-014-0218-x.

PMID:
25124362
[PubMed - in process]
Free PMC Article
9.

A direct comparison of the pharmacodynamic properties of insulin detemir and neutral protamine lispro insulin in patients with type 1 diabetes.

Korsatko S, Glettler K, Olsen KJ, Wutte A, Bock G, Koehler G, Mader JK, Semlitsch B, Pieber TR.

Diabetes Obes Metab. 2013 Mar;15(3):241-5. doi: 10.1111/dom.12016. Epub 2012 Oct 22.

PMID:
23013357
[PubMed - indexed for MEDLINE]
10.

The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.

Heise T, Eckers U, Kanc K, Nielsen JN, Nosek L.

Diabetes Technol Ther. 2008 Dec;10(6):479-85. doi: 10.1089/dia.2008.0019.

PMID:
19049377
[PubMed - indexed for MEDLINE]
11.

The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes.

Meneghini L, Atkin SL, Gough SC, Raz I, Blonde L, Shestakova M, Bain S, Johansen T, Begtrup K, Birkeland KI; NN1250-3668 (BEGIN FLEX) Trial Investigators.

Diabetes Care. 2013 Apr;36(4):858-64. doi: 10.2337/dc12-1668. Epub 2013 Jan 22.

PMID:
23340894
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): a 26-week randomized, treat-to-target trial with a 26-week extension.

Mathieu C, Hollander P, Miranda-Palma B, Cooper J, Franek E, Russell-Jones D, Larsen J, Tamer SC, Bain SC; NN1250-3770 (BEGIN: Flex T1) Trial Investigators.

J Clin Endocrinol Metab. 2013 Mar;98(3):1154-62. doi: 10.1210/jc.2012-3249. Epub 2013 Feb 7.

PMID:
23393185
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials.

Ratner RE, Gough SC, Mathieu C, Del Prato S, Bode B, Mersebach H, Endahl L, Zinman B.

Diabetes Obes Metab. 2013 Feb;15(2):175-84. doi: 10.1111/dom.12032. Epub 2012 Dec 3.

PMID:
23130654
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Effect of insulin degludec versus sitagliptin in patients with type 2 diabetes uncontrolled on oral antidiabetic agents.

Philis-Tsimikas A, Del Prato S, Satman I, Bhargava A, Dharmalingam M, Skjøth TV, Rasmussen S, Garber AJ.

Diabetes Obes Metab. 2013 Aug;15(8):760-6. doi: 10.1111/dom.12115. Epub 2013 May 6.

PMID:
23577643
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.

Hompesch M, Morrow L, Watkins E, Roepstorff C, Thomsen HF, Haahr H.

Clin Ther. 2014 Apr 1;36(4):507-15. doi: 10.1016/j.clinthera.2013.12.014. Epub 2014 Feb 5.

PMID:
24508419
[PubMed - in process]
Free Article
16.

Insulin degludec in type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine.

Birkeland KI, Home PD, Wendisch U, Ratner RE, Johansen T, Endahl LA, Lyby K, Jendle JH, Roberts AP, DeVries JH, Meneghini LF.

Diabetes Care. 2011 Mar;34(3):661-5. doi: 10.2337/dc10-1925. Epub 2011 Jan 26.

PMID:
21270174
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Similarity of pharmacodynamic effects of a single injection of insulin glargine, insulin detemir and NPH insulin on glucose metabolism assessed by 24-h euglycaemic clamp studies in healthy humans.

Sørensen LP, Brock B, Mengel A, Rungby J, Moller N, Nielsen S, Vølund A, Schmitz O.

Diabet Med. 2010 Jul;27(7):830-7. doi: 10.1111/j.1464-5491.2010.03026.x.

PMID:
20636965
[PubMed - indexed for MEDLINE]
18.
19.

Insulin degludec is not associated with a delayed or diminished response to hypoglycaemia compared with insulin glargine in type 1 diabetes: a double-blind randomised crossover study.

Koehler G, Heller S, Korsatko S, Roepstorff C, Rasmussen S, Haahr H, Pieber TR.

Diabetologia. 2014 Jan;57(1):40-9. doi: 10.1007/s00125-013-3056-0. Epub 2013 Sep 22.

PMID:
24057153
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Insulin degludec: overview of a novel ultra long-acting basal insulin.

Gough SC, Harris S, Woo V, Davies M.

Diabetes Obes Metab. 2013 Apr;15(4):301-9. doi: 10.1111/dom.12052. Epub 2013 Jan 29. Review.

PMID:
23240573
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk